Erschienen in:
01.05.2010 | Poster presentation
Topoisomerase 2 alpha as a predictor of response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer
verfasst von:
M Shehata, A Al-Attar, J Reis-Filho, I Ellis, A Mukherjee, S Chan
Erschienen in:
Breast Cancer Research
|
Sonderheft 1/2010
Einloggen, um Zugang zu erhalten
Excerpt
Anthracyclines play an important role in the treatment of breast cancer but their beneficial therapeutic effects may not be the same for all breast cancer patients. Side effects, including cardiotoxicity, may be avoided if biomarkers of response could be identified. Topoisomerase 2 alpha (Topo2α) is a target of anthracyclines and has been proposed as a chemosensitivity marker of anthracycline-containing therapies by in vitro and in vivo studies. But the method to detect it remains a controversial issue. Treatment in the neoadjvant setting is a unique opportunity to examine biomarkers of response to chemotherapy. …